Exploration of Medicine

From: Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine

Table 1. Classification of NAFLD [2, 3]

Primary NAFLD
	Associated with/predisposing to incident metabolic syndrome
Secondary NAFLD
	Nutritional disorders
		total parenteral nutrition, acute starvation
	Abdominal surgery
		extensive small bowel resection bilio-pancreatic diversion, jejunal by-pass
	Drug-induced
		diltiazem, aspirin, methotrexate, highly active antiretroviral therapy (stavudine and zidovudine)
	Occupational exposure to organic solvents
	(Rare) Metabolic disorders	hypobetalipoproteinemia, lipodystrophy, Weber-Christian syndrome, acute fatty liver of pregnancy, Reyes syndrome and Mauriac syndrome
	VAFLD
		HIV, HCV
	Common endocrine disorders
		Hypothyroidism, hypogonadism in either sex, GH deficiency, PCOS

Return to article view

Note. Reprinted from “Renaming NAFLD to MAFLD: could the LDE system assist in this transition?” by Lonardo A. J Clin Med. 2021;10:492 (https://doi.org/10.3390/jcm10030492). CC BY.

Declarations

Acknowledgment

I am indebted to my wife, Jacqueline Mole, for editing English carefully.

Author contributions

The author contributed solely to the work.

Conflicts of interest

The author declares that he has no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Lonardo A, Leoni S, Alswat KA, Fouad Y. History of nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21:5888. [DOI]

Lonardo A. Renaming NAFLD to MAFLD: could the LDE system assist in this transition? J Clin Med. 2021;10:492. [DOI] [PubMed] [PMC]

Liebe R, Esposito I, Bock HH, Vom Dahl S, Stindt J, Baumann U, et al. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol. 2021;74:1455–71. [DOI] [PubMed]

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–9. [DOI] [PubMed]

Targher G. From nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: more than a single-letter change in an acronym. Hepatoma Res. 2021;7:47. [DOI]

van der Poorten D, Samer CF, Ramezani-Moghadam M, Coulter S, Kacevska M, Schrijnders D, et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology. 2013;57:2180–8. [DOI] [PubMed]

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1121–40. [DOI] [PubMed]

Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019;70:531–44. [DOI] [PubMed]

Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into nonalcoholic fatty-liver disease heterogeneity. Semin Liver Dis. 2021;41:421–34. [DOI] [PubMed] [PMC]

10.

Non-alcoholic Fatty Liver Disease Study Group; Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015;47:997–1006. [DOI] [PubMed]

11.

Suzuki A, Diehl AM. Nonalcoholic steatohepatitis. Annu Rev Med. 2017;68:85–98. [DOI] [PubMed]

12.

Katsarou A, Moustakas II, Pyrina I, Lembessis P, Koutsilieris M, Chatzigeorgiou A. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease. World J Gastroenterol. 2020;26:1993–2011. [DOI] [PubMed] [PMC]

13.

Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537–64. [DOI] [PubMed]

14.

Pais R, Maurel T. Natural history of NAFLD. J Clin Med. 2021;10:1161. [DOI] [PubMed] [PMC]

15.

Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17:774. [DOI]

16.

Nasr P, Blomdahl J, Kechagias S, Ekstedt M. Modifiers of liver-related manifestation in the course of NAFLD. Curr Pharm Des. 2020;26:1062–78. [DOI] [PubMed]

17.

Wentworth BJ, Caldwell SH. Pearls and pitfalls in nonalcoholic fatty liver disease: tricky results are common. Metab Target Organ Damage. 2021;1:2. [DOI]

18.

Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis. 2017;49:471–83. [DOI] [PubMed]

19.

Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Explor Med. 2020;1:85–107. [DOI]

20.

Lonardo A, Arab JP, Arrese M. Perspectives on precision medicine approaches to NAFLD diagnosis and management. Adv Ther. 2021;38:2130–58. [DOI] [PubMed] [PMC]

21.

Lonardo A. Back to the future. From the history of NAFLD to MAFLD to heterogeneity of disease. Clin Transl Discovery. Forthcoming 2021.

22.

Lonardo A, Byrne CD, Targher G. Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going? Metab Target Organ Damage. 2021;1:3. [DOI]

23.

Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111S:154170. [DOI] [PubMed]

24.

Sanna C, Rosso C, Marietti M, Bugianesi E. Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci. 2016;17:717. [DOI]

25.

Pellicori P, Vaduganathan M, Ferreira JP, Zannad F, Sanyal AJ. Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design. Diabetes Metab. 2021;[Epub ahead of print]. [DOI]

26.

Martinez-Urbistondo D, Suarez Del Villar R, Argemí J, Daimiel L, Ramos-López O, San-Cristobal R, et al. Antioxidant lifestyle, co-morbidities and quality of life empowerment concerning liver fibrosis. Antioxidants (Basel). 2020;9:1125. [DOI]

27.

Delli Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, Vajro P. Oxidative stress in non-alcoholic fatty liver disease. An updated mini review. Front Med (Lausanne). 2021;8:595371. [DOI] [PubMed] [PMC]

28.

Christinat N, Valsesia A, Masoodi M. Untargeted profiling of bile acids and lysophospholipids identifies the lipid signature associated with glycemic outcome in an obese non-diabetic clinical cohort. Biomolecules. 2020;10:1049. [DOI]

29.

Mato JM, Alonso C, Noureddin M, Lu SC. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25:3009–20. [DOI] [PubMed] [PMC]

30.

Jiao N, Loomba R, Yang ZH, Wu D, Fang S, Bettencourt R, et al. Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. Physiol Genomics. 2021;53:336–48. [DOI] [PubMed] [PMC]

31.

Mahgoub A, Steer CJ. MicroRNAs in the evaluation and potential treatment of liver diseases. J Clin Med. 2016;5:52. [DOI]

32.

Nielsen J. Systems biology of metabolism: a driver for developing personalized and precision medicine. Cell Metab. 2017;25:572–9. [DOI] [PubMed]

33.

Sharpton SR, Schnabl B, Knight R, Loomba R. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease. Cell Metab. 2021;33:21–32. [DOI] [PubMed] [PMC]

34.

Kurt Z, Barrere-Cain R, LaGuardia J, Mehrabian M, Pan C, Hui ST, et al. Tissue-specific pathways and networks underlying sexual dimorphism in non-alcoholic fatty liver disease. Biol Sex Differ. 2018;9:46. [DOI] [PubMed] [PMC]

35.

Steinman JB, Salomao MA, Pajvani UB. Zonation in NASH - a key paradigm for understanding pathophysiology and clinical outcomes. Liver Int. 2021;41:2534–46. [DOI]

36.

Houghton D, Stewart CJ, Day CP, Trenell M. Gut microbiota and lifestyle interventions in NAFLD. Int J Mol Sci. 2016;17:447. [DOI] [PubMed] [PMC]

37.

Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 2016;311:G1018–36. [DOI] [PubMed] [PMC]

38.

Hartmann P, Schnabl B. New developments in microbiome in alcohol-associated and nonalcoholic fatty liver disease. Semin Liver Dis. 2021;41:87–102. [DOI] [PubMed] [PMC]

39.

Chien Y, Huang CS, Lin HC, Lu KH, Tsai PH, Lai YH, et al. Improvement of non-alcoholic steatohepatitis by hepatocyte-like cells generated from iPSCs with Oct4/Sox2/Klf4/Parp1. Oncotarget. 2018;9:18594–606. [DOI] [PubMed] [PMC]

40.

Murray JK, Long J, Liu L, Singh S, Pruitt D, Ollmann M, et al. Identification and optimization of a minor allele-specific small interfering RNA to prevent PNPLA3 I148M-driven nonalcoholic fatty liver disease. Nucleic Acid Ther. 2021;31:324–40. [DOI] [PubMed]

41.

Lorbek G, Urlep Ž, Rozman D. Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease. Pharmacogenomics. 2016;17:1273–88. [DOI] [PubMed]

42.

Schwartz BE, Rajagopal V, Smith C, Cohick E, Whissell G, Gamboa M, et al. Discovery and targeting of the signaling controls of PNPLA3 to effectively reduce transcription, expression, and function in pre-clinical NAFLD/NASH settings. Cells. 2020;9:2247. [DOI]

43.

Czaja AJ. Recurrence of nonalcoholic steatohepatitis after liver transplantation. Liver Transpl Surg. 1997;3:185–6. [DOI] [PubMed]